Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief

Daiichi Sankyo’s anticoagulant edoxaban can cater to some 80% of the population subject to treatments with novel oral anticoagulants (NOACs) in the US even with restricted indications granted by the FDA, the company’s US commercial head suggested on February 17...read more